JWH-142

JWH-142 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent agonist at both the CB1 and CB2 cannabinoid receptors, with a slight preference for the CB2 receptor. JWH-142 was developed by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.

Chemical Structure and Properties

JWH-142 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure consists of a naphthalene ring system linked to an indole group via a methanone bridge. The presence of a methoxy group on the naphthalene ring distinguishes JWH-142 from other compounds in the JWH series.

The molecular formula of JWH-142 is C24H23NO2, and it has a molar mass of 357.44 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.

Pharmacology

JWH-142 acts as a full agonist at the CB1 and CB2 receptors, which are part of the endocannabinoid system. The CB1 receptor is primarily located in the central nervous system, while the CB2 receptor is found mainly in the peripheral tissues and immune cells. JWH-142's affinity for these receptors results in effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

The compound's binding affinity and efficacy at the CB2 receptor suggest potential applications in the modulation of immune responses and inflammation. However, the psychoactive effects mediated through the CB1 receptor limit its therapeutic use due to potential side effects such as altered perception, mood changes, and cognitive impairment.

Legal Status

The legal status of JWH-142 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. The compound is often included in legislation targeting synthetic cannabinoids and "designer drugs."

Research and Applications

Research on JWH-142 and related compounds has primarily focused on understanding the structure-activity relationships of cannabinoids and their potential therapeutic applications. Studies have explored the use of synthetic cannabinoids in pain management, appetite stimulation, and the treatment of certain neurological disorders.

However, the recreational use of synthetic cannabinoids like JWH-142 has raised concerns due to their unpredictable effects and potential for harm. Adverse effects can include anxiety, paranoia, tachycardia, and in severe cases, psychosis or seizures.

Also see

• Synthetic cannabinoids
• JWH-018
• Cannabinoid receptor
• Endocannabinoid system
• John W. Huffman